Sirolimus - Veloxis Pharmaceuticals

Drug Profile

Sirolimus - Veloxis Pharmaceuticals

Alternative Names: LCP-Siro

Latest Information Update: 12 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LifeCycle Pharma
  • Developer Veloxis Pharmaceuticals
  • Class Anti-infectives; Antiepileptic drugs; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Jun 2011 Sirolimus - LifeCycle Pharma is still available for licensing (http://www.lifecyclepharma.com/)
  • 29 Nov 2007 Phase-I clinical trials in Autoimmune disorders in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top